Craig-Hallum downgraded Skye Bioscience (SKYE) to Hold from Buy with a $2 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Fifth Third buying Comerica, AMD gets OpenAI boost: Morning Buzz
- Promising Phase IIa Results and Favorable Safety Profile Drive Buy Rating for Skye Bioscience’s Nimacimab
- Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald
- Skye Bioscience Reveals Phase 2a Study Results
- Why Is Skye Bioscience Stock Down 60% Today?